{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:34:03Z","timestamp":1792679643549,"version":"4.5.0"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"22","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Combination chemotherapy regimen incorporating CD20 antibodies are commonly used in the treatment of CD20-positive non\u2013Hodgkin's lymphoma (NHL). Fludarabine phosphate (F-araAMP), cyclophosphamide, and CD20 antibodies (Rituximab) constitute the FCR regimen for treating selected NHL, including aggressive mantle cell lymphoma (MCL). As an alternative to the CD20 antibody, we generated a CD20-targeted measles virus (MV)\u2013based vector. This vector was also armed with the prodrug convertase purine nucleoside phosphorylase (PNP) that locally converts the active metabolite of F-araAMP to a highly diffusible substance capable of efficiently killing bystander cells. We showed in infected cells that early prodrug administration controls vector spread, whereas late administration enhances cell killing. Control of spread by early prodrug administration was also shown in an animal model: F-araAMP protected genetically modified mice susceptible to MV infection from a potentially lethal intracerebral challenge. Enhanced oncolytic potency after extensive infection was shown in a Burkitt's lymphoma xenograft model (Raji cells): After systemic vector inoculation, prodrug administration enhanced the therapeutic effect synergistically. In a MCL xenograft model (Granta 519 cells), intratumoral (i.t.) vector administration alone had high oncolytic efficacy: All mice experienced complete but temporary tumor regression, and survival was two to four times longer than that of untreated mice. Cells from MCL patients were shown to be sensitive to infection. Thus, synergy of F-araAMP with a PNP-armed and CD20-targeted MV was shown in one lymphoma therapy model after systemic vector inoculation. [Cancer Res 2007;67(22):10939\u201347]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-1252","type":"journal-article","created":{"date-parts":[[2007,11,15]],"date-time":"2007-11-15T20:23:37Z","timestamp":1195158217000},"page":"10939-10947","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Lymphoma Chemovirotherapy: CD20-Targeted and Convertase-Armed Measles Virus Can Synergize with Fludarabine"],"prefix":"10.1158","volume":"67","author":[{"given":"Guy","family":"Ungerechts","sequence":"first","affiliation":[{"name":"1Molecular Medicine Program and Virology and Gene Therapy Track, Mayo Clinic College of Medicine, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Springfeld","sequence":"additional","affiliation":[{"name":"1Molecular Medicine Program and Virology and Gene Therapy Track, Mayo Clinic College of Medicine, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie E.","family":"Frenzke","sequence":"additional","affiliation":[{"name":"1Molecular Medicine Program and Virology and Gene Therapy Track, Mayo Clinic College of Medicine, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Lampe","sequence":"additional","affiliation":[{"name":"1Molecular Medicine Program and Virology and Gene Therapy Track, Mayo Clinic College of Medicine, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Johnston","sequence":"additional","affiliation":[{"name":"1Molecular Medicine Program and Virology and Gene Therapy Track, Mayo Clinic College of Medicine, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"Parker","sequence":"additional","affiliation":[{"name":"2Southern Research Institute and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Sorscher","sequence":"additional","affiliation":[{"name":"3University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"1Molecular Medicine Program and Virology and Gene Therapy Track, Mayo Clinic College of Medicine, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,11,15]]},"reference":[{"key":"2022061623213206500_B1","doi-asserted-by":"crossref","unstructured":"Chiocca EA. Oncolytic viruses. Nat Rev Cancer\u20082002; 2: 938\u201350.","DOI":"10.1038\/nrc948"},{"key":"2022061623213206500_B2","doi-asserted-by":"crossref","unstructured":"Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer\u20082005; 5: 965\u201376.","DOI":"10.1038\/nrc1750"},{"key":"2022061623213206500_B3","doi-asserted-by":"crossref","unstructured":"Liu TC, Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res\u20082007; 67: 429\u201332.","DOI":"10.1158\/0008-5472.CAN-06-2871"},{"key":"2022061623213206500_B4","doi-asserted-by":"crossref","unstructured":"Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med\u20082000; 6: 879\u201385.","DOI":"10.1038\/78638"},{"key":"2022061623213206500_B5","unstructured":"DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res\u20082001; 61: 7464\u201372."},{"key":"2022061623213206500_B6","unstructured":"Freytag SO, Stricker H, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res\u20082003; 63: 7497\u2013506."},{"key":"2022061623213206500_B7","doi-asserted-by":"crossref","unstructured":"Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst\u20082006; 98: 298\u2013300.","DOI":"10.1093\/jnci\/djj111"},{"key":"2022061623213206500_B8","doi-asserted-by":"crossref","unstructured":"Heinzerling L, Kunzi V, Oberholzer PA, Kundig T, Naim H, Dummer R. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood\u20082005; 106: 2287\u201394.","DOI":"10.1182\/blood-2004-11-4558"},{"key":"2022061623213206500_B9","doi-asserted-by":"crossref","unstructured":"Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet\u20081971; 2: 105\u20136.","DOI":"10.1016\/S0140-6736(71)92086-1"},{"key":"2022061623213206500_B10","doi-asserted-by":"crossref","unstructured":"Pasquinucci G. Possible effect of measles on leukaemia. Lancet\u20081971; 1: 136.","DOI":"10.1016\/S0140-6736(71)90869-5"},{"key":"2022061623213206500_B11","doi-asserted-by":"crossref","unstructured":"Grote D, Russell SJ, Cornu TI, et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood\u20082001; 97: 3746\u201354.","DOI":"10.1182\/blood.V97.12.3746"},{"key":"2022061623213206500_B12","doi-asserted-by":"crossref","unstructured":"Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R, Russell SJ. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood\u20082001; 98: 2002\u20137.","DOI":"10.1182\/blood.V98.7.2002"},{"key":"2022061623213206500_B13","doi-asserted-by":"crossref","unstructured":"Schneider U, Bullough F, Vongpunsawad S, Russell SJ, Cattaneo R. Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol\u20082000; 74: 9928\u201336.","DOI":"10.1128\/JVI.74.21.9928-9936.2000"},{"key":"2022061623213206500_B14","doi-asserted-by":"crossref","unstructured":"Hammond AL, Plemper RK, Zhang J, Schneider U, Russell SJ, Cattaneo R. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol\u20082001; 75: 2087\u201396.","DOI":"10.1128\/JVI.75.5.2087-2096.2001"},{"key":"2022061623213206500_B15","doi-asserted-by":"crossref","unstructured":"Bucheit AD, Kumar S, Grote DM, et al. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther\u20082003; 7: 62\u201372.","DOI":"10.1016\/S1525-0016(02)00033-3"},{"key":"2022061623213206500_B16","doi-asserted-by":"crossref","unstructured":"Peng KW, Donovan KA, Schneider U, Cattaneo R, Lust JA, Russell SJ. Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood\u20082003; 101: 2557\u201362.","DOI":"10.1182\/blood-2002-07-2195"},{"key":"2022061623213206500_B17","doi-asserted-by":"crossref","unstructured":"Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature\u20082000; 406: 893\u20137.","DOI":"10.1038\/35022579"},{"key":"2022061623213206500_B18","doi-asserted-by":"crossref","unstructured":"Dorig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell\u20081993; 75: 295\u2013305.","DOI":"10.1016\/0092-8674(93)80071-L"},{"key":"2022061623213206500_B19","doi-asserted-by":"crossref","unstructured":"Vongpunsawad S, Oezgun N, Braun W, Cattaneo R. Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model. J Virol\u20082004; 78: 302\u201313.","DOI":"10.1128\/JVI.78.1.302-313.2004"},{"key":"2022061623213206500_B20","doi-asserted-by":"crossref","unstructured":"Nakamura T, Peng KW, Vongpunsawad S, et al. Antibody-targeted cell fusion. Nat Biotechnol\u20082004; 22: 331\u20136.","DOI":"10.1038\/nbt942"},{"key":"2022061623213206500_B21","doi-asserted-by":"crossref","unstructured":"Nakamura T, Peng KW, Harvey M, et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol\u20082005; 23: 209\u201314.","DOI":"10.1038\/nbt1060"},{"key":"2022061623213206500_B22","unstructured":"American Cancer Society. Cancer Facts and Figures 2007. Atlanta (GA): American Cancer Society; 2007."},{"key":"2022061623213206500_B23","doi-asserted-by":"crossref","unstructured":"Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer\u20082001; 1: 118\u201329.","DOI":"10.1038\/35101072"},{"key":"2022061623213206500_B24","doi-asserted-by":"crossref","unstructured":"Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood\u20082002; 100: 3115\u201320.","DOI":"10.1182\/blood-2002-03-0972"},{"key":"2022061623213206500_B25","doi-asserted-by":"crossref","unstructured":"Elter T, Hallek M, Engert A. Fludarabine in chronic lymphocytic leukaemia. Expert Opin Pharmacother\u20082006; 7: 1641\u201351.","DOI":"10.1517\/14656566.7.12.1641"},{"key":"2022061623213206500_B26","unstructured":"McLaughlin P, Deans JP. CD20-B-cell antigen and therapeutic target. In: Hilmen P, editor. Therapeutic strategies in lymphoid malignancies. Oxford: Atlas Medical Publishing, Ltd.; 2005. p. 36\u201344."},{"key":"2022061623213206500_B27","doi-asserted-by":"crossref","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol\u20081998; 16: 2825\u201333.","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"2022061623213206500_B28","doi-asserted-by":"crossref","unstructured":"Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol\u20082002; 29: 2\u20139.","DOI":"10.1053\/sonc.2002.30156"},{"key":"2022061623213206500_B29","doi-asserted-by":"crossref","unstructured":"Parker WB, Allan PW, Shaddix SC, et al. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol\u20081998; 55: 1673\u201381.","DOI":"10.1016\/S0006-2952(98)00034-3"},{"key":"2022061623213206500_B30","doi-asserted-by":"crossref","unstructured":"Jadayel DM, Lukas J, Nacheva E, et al. Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519). Leukemia\u20081997; 11: 64\u201372.","DOI":"10.1038\/sj.leu.2400555"},{"key":"2022061623213206500_B31","doi-asserted-by":"crossref","unstructured":"Ono N, Tatsuo H, Hidaka Y, Aoki T, Minagawa H, Yanagi Y. Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J Virol\u20082001; 75: 4399\u2013401.","DOI":"10.1128\/JVI.75.9.4399-4401.2001"},{"key":"2022061623213206500_B32","unstructured":"Sorscher EJ, Peng S, Bebok Z, Allan PW, Bennett LL, Jr., Parker WB. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther\u20081994; 1: 233\u20138."},{"key":"2022061623213206500_B33","doi-asserted-by":"crossref","unstructured":"Kaerber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Pathol Pharmakol\u20081931; 162: 480\u20133.","DOI":"10.1007\/BF01863914"},{"key":"2022061623213206500_B34","doi-asserted-by":"crossref","unstructured":"Parker WB, Allan PW, Hassan AE, Secrist JA III, Sorscher EJ, Waud WR. Antitumor activity of 2-fluoro-2\u2032-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther\u20082003; 10: 23\u20139.","DOI":"10.1038\/sj.cgt.7700520"},{"key":"2022061623213206500_B35","doi-asserted-by":"crossref","unstructured":"Peng KW, Frenzke M, Myers R, et al. Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice. Hum Gene Ther\u20082003; 14: 1565\u201377.","DOI":"10.1089\/104303403322495070"},{"key":"2022061623213206500_B36","doi-asserted-by":"crossref","unstructured":"Mrkic B, Pavlovic J, Rulicke T, et al. Measles virus spread and pathogenesis in genetically modified mice. J Virol\u20081998; 72: 7420\u20137.","DOI":"10.1128\/JVI.72.9.7420-7427.1998"},{"key":"2022061623213206500_B37","doi-asserted-by":"crossref","unstructured":"Gadi VK, Alexander SD, Kudlow JE, Allan P, Parker WB, Sorscher EJ. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther\u20082000; 7: 1738\u201343.","DOI":"10.1038\/sj.gt.3301286"},{"key":"2022061623213206500_B38","doi-asserted-by":"crossref","unstructured":"Drexler HG, MacLeod RA. Malignant hematopoietic cell lines: in vitro models for the study of mantle cell lymphoma. Leuk Res\u20082002; 26: 781\u20137.","DOI":"10.1016\/S0145-2126(02)00026-7"},{"key":"2022061623213206500_B39","doi-asserted-by":"crossref","unstructured":"Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther\u20082005; 12: 141\u201361.","DOI":"10.1038\/sj.cgt.7700771"},{"key":"2022061623213206500_B40","doi-asserted-by":"crossref","unstructured":"Pawlik TM, Nakamura H, Mullen JT, et al. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer\u20082002; 95: 1171\u201381.","DOI":"10.1002\/cncr.10776"},{"key":"2022061623213206500_B41","doi-asserted-by":"crossref","unstructured":"Seo E, Abei M, Wakayama M, et al. Effective gene therapy of biliary tract cancers by a conditionally replicative adenovirus expressing uracil phosphoribosyltransferase: significance of timing of 5-fluorouracil administration. Cancer Res\u20082005; 65: 546\u201352.","DOI":"10.1158\/0008-5472.546.65.2"},{"key":"2022061623213206500_B42","unstructured":"Boviatsis EJ, Park JS, Sena-Esteves M, et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res\u20081994; 54: 5745\u201351."},{"key":"2022061623213206500_B43","doi-asserted-by":"crossref","unstructured":"Wildner O, Hoffmann D, Jogler C, Uberla K. Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs. Cancer Gene Ther\u20082003; 10: 791\u2013802.","DOI":"10.1038\/sj.cgt.7700638"},{"key":"2022061623213206500_B44","doi-asserted-by":"crossref","unstructured":"Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med\u20082002; 8: 527\u201331.","DOI":"10.1038\/nm0502-527"},{"key":"2022061623213206500_B45","doi-asserted-by":"crossref","unstructured":"Ungerechts G, Springfeld C, Frenzke ME, et al. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther. Epub 2007 Aug 21.","DOI":"10.1038\/sj.mt.6300291"},{"key":"2022061623213206500_B46","unstructured":"Hirasawa K, Nishikawa SG, Norman KL, et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res\u20082003; 63: 348\u201353."},{"key":"2022061623213206500_B47","doi-asserted-by":"crossref","unstructured":"Fulci G, Breymann L, Gianni D, et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A\u20082006; 103: 12873\u20138.","DOI":"10.1073\/pnas.0605496103"},{"key":"2022061623213206500_B48","doi-asserted-by":"crossref","unstructured":"Di Paolo NC, Tuve S, Ni S, Hellstrom KE, Hellstrom I, Lieber A. Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. Cancer Res\u20082006; 66: 960\u20139.","DOI":"10.1158\/0008-5472.CAN-05-2388"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/22\/10939\/2574670\/10939.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/22\/10939\/2574670\/10939.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T02:53:40Z","timestamp":1655434420000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/22\/10939\/533635\/Lymphoma-Chemovirotherapy-CD20-Targeted-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,15]]},"references-count":48,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2007,11,15]]},"published-print":{"date-parts":[[2007,11,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-1252","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,15]]}}}